Skip to content
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Endocrinology · Maturity-Onset Diabetes of the Young

Can You Switch Insulin to Sulfonylureas Safely in MODY?

At a Glance

People with confirmed HNF1A- or HNF4A-MODY may be able to replace insulin with a very low dose of a sulfonylurea if they still make insulin, but the change must be supervised closely because severe, prolonged low blood sugar can occur.

If you have been diagnosed with HNF1A-MODY or HNF4A-MODY and are currently taking insulin, it is often possible to transition safely to a class of oral diabetes medications called sulfonylureas [1][2]. Because individuals with these specific types of MODY are exceptionally sensitive to sulfonylureas, this transition can successfully replace insulin therapy for many patients [3][4]. However, because of this extreme sensitivity, the switch carries a high risk of severe low blood sugar (hypoglycemia) and must be done very slowly, with very low doses, and under the close supervision of an endocrinologist experienced in monogenic diabetes [3][4][5].

Why Sulfonylureas Work for HNF1A and HNF4A MODY

To understand why this switch works, it helps to know how these types of MODY affect your body. HNF1A and HNF4A MODY are caused by genetic changes that affect how your beta cells (the insulin-producing cells in the pancreas) sense glucose [3]. Your pancreas can still make insulin, but it doesn’t release enough of it when your blood sugar rises.

Sulfonylureas work by bypassing this broken sensing mechanism; they bind to specific channels on the beta cells and trigger insulin release with less dependence on how high your blood sugar is [3]. People with HNF1A- and HNF4A-MODY are incredibly sensitive to these drugs [3][4]. A dose that would barely affect someone with typical type 2 diabetes can cause a marked and prolonged release of insulin in someone with MODY, leading to sudden and severe hypoglycemia [3][4][5].

Before You Switch: Assessing Eligibility

Do not attempt to reduce or stop your insulin on your own. A transition should only be considered if a monogenic-diabetes specialist has confirmed all of the following:

  • Confirmed Diagnosis: You have a confirmed pathogenic or likely pathogenic genetic variant in the HNF1A or HNF4A gene [1].
  • Residual Insulin Production: You still produce your own insulin (often measured by a C-peptide blood test). If your body no longer makes insulin, pills will not work [6][7].
  • Kidney and Liver Health: Your kidney and liver function have been checked, as impairment can cause sulfonylureas to build up in your system and cause severe lows [8][9].

The Clinical Protocol for Transitioning

Because every patient’s situation is unique, there is no single universal schedule for stopping insulin and starting a sulfonylurea [10][11]. The transition timing depends on your current insulin type, doses, and glucose patterns. However, the clinical protocol generally follows these core safety principles:

  • Start extremely low: The starting dose of a sulfonylurea (such as gliclazide or glimepiride) will be a fraction of the typical starting dose [3][4]. For example, medical literature describes successful transitions using an illustrative starting dose of just 20 mg per day of an immediate-release gliclazide formulation—though your exact medication, formulation, and dose will be uniquely prescribed by your specialist [3][4][5].
  • Supervised insulin withdrawal: Your doctor will provide a specific, written plan for reducing your insulin injections while introducing the pill [10][12].
  • Intense glucose monitoring: The use of a Continuous Glucose Monitor (CGM) is frequently utilized by specialists to track your glucose levels and catch rapid drops [13][14]. However, because CGMs measure glucose in tissue fluid and have a slight lag, you must always confirm a low reading (or a reading that doesn’t match your symptoms) with a fingerstick blood test.

Emergency Plans: Managing the Risks

The extreme sensitivity to sulfonylureas means you must be prepared for two main risks: severe hypoglycemia and, less commonly, diabetic ketoacidosis.

Severe Hypoglycemia (Low Blood Sugar)

The primary risk during this switch is hypoglycemia [3]. Sulfonylurea-induced lows can be prolonged and recur even after treatment. Ask your doctor for specific glucose thresholds, but generally, a blood sugar below 70 mg/dL (3.9 mmol/L) requires action [15].

What to do:

  • Recognize symptoms: Shaking, sweating, rapid heartbeat, confusion, or dizziness.
  • Treat immediately: If you are awake and able to swallow, consume 15 grams of fast-acting carbohydrate (like glucose tabs or juice) and recheck in 15 minutes.
  • Severe lows: If you lose consciousness or have a seizure, someone else must help you. Never put food or drink in an unconscious person’s mouth. Your household should be trained to administer prescription glucagon (a rescue medication that rapidly raises blood sugar) and call emergency services immediately.
  • Precautions: Always carry fast-acting glucose, avoid driving during the transition period, and recognize that alcohol, exercise, or missed meals can significantly increase your risk of a low [15][16].

Hyperglycemia and Diabetic Ketoacidosis (DKA)

If your body does not respond to the pill and you stop taking your insulin, your blood sugar will rise. In severe cases of insulin deficiency—such as missing medication or having an incorrect diagnosis—this can lead to Diabetic Ketoacidosis (DKA), a dangerous condition where your blood becomes acidic [15][17].

Warning Signs of DKA:

  • Persistent high blood sugar levels.
  • Nausea, vomiting, or abdominal pain.
  • Deep, rapid breathing or a fruity odor to the breath.
  • Severe dehydration or confusion.

Your doctor should provide “sick-day rules” explaining when to test your blood or urine for ketones (acidic chemicals made when the body burns fat instead of glucose) and exactly when to contact the medical team for persistent highs [15][17].

Factors That May Affect Whether Switching is Appropriate

While sulfonylureas are a common treatment, they aren’t right for everyone with HNF1A or HNF4A MODY [1][18]:

  • Pregnancy: If you are planning a pregnancy or become pregnant, you need prompt specialist and obstetric review. Sulfonylureas cross the placenta and can cause the baby to produce too much insulin [19][20]. Therefore, transitioning back to insulin is often preferred during pregnancy [21][22]. Never stop your medication abruptly; your doctor will create an individualized plan.
  • Progressive Beta-Cell Failure: Over many years, the pancreas can slowly lose its ability to produce insulin altogether [6][7]. If you have had diabetes for decades and lack residual insulin, a sulfonylurea may not work, and insulin will still be necessary [6][18].
  • Specific Genetic Variants: Response to sulfonylureas can vary based on your specific genetic mutation. Some variants are known to respond poorly to these medications [23][6].

If sulfonylureas cause unmanageable low blood sugars or fail to control your glucose, your doctor will likely recommend returning to insulin or exploring other specialized treatments [6][18][13].

Common questions in this guide

Can someone with HNF1A or HNF4A MODY switch from insulin to a sulfonylurea?
Many people can make this switch if genetic testing confirms HNF1A- or HNF4A-MODY and the pancreas still produces insulin. A specialist must also review C-peptide, kidney and liver function, current glucose patterns, and the specific genetic variant before recommending a change.
Why are sulfonylureas so effective in some types of MODY?
HNF1A and HNF4A changes can interfere with how pancreatic beta cells sense glucose and release insulin. Sulfonylureas stimulate insulin release through another pathway, but people with these types of MODY can be extremely sensitive to them.
How should insulin be reduced when starting a sulfonylurea for MODY?
The sulfonylurea is usually started at a very low dose while insulin is reduced according to an individualized written plan. Frequent glucose checks, often with a continuous glucose monitor plus a fingerstick meter, help the care team adjust treatment safely.
What is the biggest danger when switching from insulin to a sulfonylurea?
The main danger is severe, prolonged, or recurring low blood sugar. Shaking, sweating, a fast heartbeat, dizziness, or confusion require prompt action, and household members should know how to use prescribed glucagon and call emergency services for an unconscious person or someone having a seizure.
Could stopping insulin cause diabetic ketoacidosis during the switch?
Yes, if the sulfonylurea does not provide enough insulin release, blood sugar can rise and diabetic ketoacidosis can occur. A specialist should provide sick-day instructions covering glucose and ketone testing and when to seek urgent medical help.
Is switching from insulin to a sulfonylurea safe during pregnancy?
Pregnancy requires prompt review by an endocrinologist and an obstetric team because sulfonylureas cross the placenta and may affect the baby. Insulin is often preferred during pregnancy, but medication should never be stopped or changed abruptly without a supervised plan.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my specific HNF1A/HNF4A variant and my current C-peptide levels, what is my likelihood of a successful transition off insulin?
  2. 2.What exact dose and formulation of sulfonylurea will we start with, and how will my kidney and liver function affect my risk?
  3. 3.Can you provide a written, step-by-step protocol for tapering down my insulin while starting the pills?
  4. 4.What are my specific 'sick-day rules', and at what blood sugar or ketone levels should I contact you or go to the emergency room?
  5. 5.How should I handle meals, exercise, and driving during this transition period?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Treatment Options for Patients with Maturity-Onset Diabetes of the Young (MODY): A Systematic Review of Literature: 2026 Update.

    Zagaroli L, Di Berardino A, Petragnano F, et al.

    Diabetes therapy : research, treatment and education of diabetes and related disorders 2026; (17(7)):959-983 doi:10.1007/s13300-026-01884-2.

    PMID: 42295651
  2. 2

    Maturity Onset Diabetes of the Young (MODY): French National Diagnosis and Care Protocol (PNDS, Protocole National de Diagnostic et de Soins).

    Dubois-Laforgue D, Donadille B, Ciangura C, et al.

    Orphanet journal of rare diseases 2026; (17(Suppl 1)).

    PMID: 42227416
  3. 3

    Hypoglycemia and antihyperglycemic treatment in adult MODY patients - A systematic review of literature.

    Urbanova J, Brunerova L, Broz J

    Diabetes research and clinical practice 2019; (158()):107914 doi:10.1016/j.diabres.2019.107914.

    PMID: 31682881
  4. 4

    HNF1A mutation in a Thai patient with maturity-onset diabetes of the young: A case report.

    Plengvidhya N, Tangjittipokin W, Teerawattanapong N, et al.

    World journal of diabetes 2019; (10(7)):414-420 doi:10.4239/wjd.v10.i7.414.

    PMID: 31363388
  5. 5

    Novel HNF1A gene mutation in maturity-onset diabetes of the young: A case report.

    Xu Q, Kan CX, Hou NN, Sun XD

    World journal of clinical cases 2022; (10(6)):1909-1913 doi:10.12998/wjcc.v10.i6.1909.

    PMID: 35317157
  6. 6

    Response to multiple glucose-lowering agents in a sib-pair with a novel HNF1α (MODY3) variant.

    Tan CSH, Ang SF, Lim SC

    European journal of human genetics : EJHG 2020; (28(4)):518-520 doi:10.1038/s41431-019-0561-8.

    PMID: 31844173
  7. 7

    [Current treatment options in Maturity-Onset Diabetes of the Young].

    Brunerová L, Urbanová J, Brož J

    Vnitrni lekarstvi 2018; (64(4)):375-379.

    PMID: 29791172
  8. 8

    Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a(-/-) Model.

    Urbanova J, Andel M, Potockova J, et al.

    Current pharmaceutical design 2015; (21(39)):5736-48 doi:10.2174/1381612821666151008124036.

    PMID: 26446475
  9. 9

    A Woman With HNF1A-Associated Monogenic Diabetes Treated Successfully With Repaglinide Monotherapy.

    Cuan K, Bass IR

    AACE clinical case reports 2024; (10(2)):49-51 doi:10.1016/j.aace.2023.12.003.

    PMID: 38523849
  10. 10

    Gliclazide Challenge Testing as an Alternative Diagnostic Tool for Hepatocyte Nuclear Factor-1-Alpha Maturity Onset Diabetes of the Young.

    Pandya S, Khairati R, Mann J, et al.

    European journal of case reports in internal medicine 2025; (12(12)):005892 doi:10.12890/2025_005892.

    PMID: 41377795
  11. 11

    Case Report: Identification of a HNF1A exons 1-10 heterozygous deletion in a Chinese MODY family.

    Lei M, Xue M, Wang H, et al.

    Frontiers in endocrinology 2026; (17()):1743021 doi:10.3389/fendo.2026.1743021.

    PMID: 41778156
  12. 12

    Treatment switch from multiple daily insulin injections to sulphonylureas in an African young adult diagnosed with HNF1A MODY: a case report.

    Katte JC, Dehayem MY, Colclough K, Sobngwi E

    Journal of medical case reports 2024; (18(1)):506 doi:10.1186/s13256-024-04850-3.

    PMID: 39420387
  13. 13

    Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA).

    Christensen AS, Hædersdal S, Støy J, et al.

    Diabetes care 2020; (43(9)):2025-2033 doi:10.2337/dc20-0408.

    PMID: 32661107
  14. 14

    A Case of Oral Semaglutide for Treatment of Hepatocyte Nuclear Factor 4A Maturity-Onset Diabetes of the Young.

    Grennan KN, Singh D, Chindris AM, Wilson JR

    AACE endocrinology and diabetes 2026; (13(2)):177-179 doi:10.1016/j.aed.2025.12.002.

    PMID: 41938282
  15. 15

    Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.

    Østoft SH

    Danish medical journal 2015; (62(9)).

    PMID: 26324089
  16. 16

    Prolonged episodes of hypoglycaemia in HNF4A-MODY mutation carriers with IGT. Evidence of persistent hyperinsulinism into early adulthood.

    Bacon S, Kyithar MP, Condron EM, et al.

    Acta diabetologica 2016; (53(6)):965-972 doi:10.1007/s00592-016-0890-9.

    PMID: 27552834
  17. 17

    Diabetic ketoacidosis in the setting of HNF1A-maturity onset diabetes of the young.

    Egan AM, Cunningham A, Jafar-Mohammadi B, Dunne FP

    BMJ case reports 2015; (2015()).

    PMID: 25837654
  18. 18

    Novel Treatment Options in Patients with Maturity-Onset Diabetes of the Young.

    Müssig K

    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2025; (133(1)):51-58 doi:10.1055/a-2436-7723.

    PMID: 39379059
  19. 19

    Management of sulfonylurea-treated monogenic diabetes in pregnancy: implications of placental glibenclamide transfer.

    Shepherd M, Brook AJ, Chakera AJ, Hattersley AT

    Diabetic medicine : a journal of the British Diabetic Association 2017; (34(10)):1332-1339 doi:10.1111/dme.13388.

    PMID: 28556992
  20. 20

    Clinical Management of Women with Monogenic Diabetes During Pregnancy.

    Dickens LT, Naylor RN

    Current diabetes reports 2018; (18(3)):12 doi:10.1007/s11892-018-0982-8.

    PMID: 29450745
  21. 21

    Management of monogenic diabetes in pregnancy: A narrative review.

    Jeeyavudeen MS, Murray SR, Strachan MWJ

    World journal of diabetes 2024; (15(1)):15-23 doi:10.4239/wjd.v15.i1.15.

    PMID: 38313847
  22. 22

    When to Consider a Diagnosis of Maturity-Onset Diabetes of the Young: Precise Diagnosis Leads to Better Management and Quality of Life for the Patients.

    Gao Y, Shekhda KM, Ali SN

    Avicenna journal of medicine 2025; (15(1)):41-45 doi:10.1055/s-0045-1802584.

    PMID: 40395699
  23. 23

    The Common p.R114W HNF4A Mutation Causes a Distinct Clinical Subtype of Monogenic Diabetes.

    Laver TW, Colclough K, Shepherd M, et al.

    Diabetes 2016; (65(10)):3212-7 doi:10.2337/db16-0628.

    PMID: 27486234

This page is for informational purposes only and does not constitute medical advice about changing diabetes medicines. Never reduce or stop insulin or start a sulfonylurea without an endocrinologist's written plan.

Get notified when new evidence is published on MODY.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.